sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street

View original at finance.yahoo.com
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street The consensus forecast among Wall Street analysts says the S&P 500(SNPINDEX: ^GSPC) will reach 8,338 in the next year, according to FactSet Research…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors are worried that hyperscalers are overspending on AI infrastructure

    60% confidence
  • S&P 500 will reach 8,338 in the next year

    60% confidence
  • The information technology sector will reach 7,215 over the next year, implying 39% upside from its current level of 5,203

    60% confidence
  • Information technology sector will reach 7,215 over the next year

    60% confidence
  • Investors are concerned that AI will disrupt the software industry

    60% confidence
  • Consumer discretionary sector will reach 2,244 over the next year

    60% confidence
  • Investors are worried that hyperscalers are overspending on AI infrastructure

    60% confidence
  • Information technology sector will reach 7,215 over the next year, implying 39% upside

    60% confidence
  • AI may be the most transformative technology in decades

    60% confidence
  • Consumer discretionary sector target implies 30% upside from current level of 1,725

    60% confidence
  • AI may be the most transformative technology in decades

    60% confidence
  • S&P 500 forecast implies 28% upside from current level

    60% confidence
  • Information technology sector was the best-performing stock market sector during the last decade due to proliferation of cloud computing and artificial intelligence

    60% confidence
  • Investors are worried that hyperscalers are overspending on AI infrastructure

    60% confidence
  • Information technology sector target implies 39% upside from current level of 5,203

    60% confidence
  • Investors are concerned that AI will disrupt the software industry

    60% confidence
  • S&P 500 target of 8,338 implies 28% upside from current level of 6,506

    60% confidence
  • The consumer discretionary sector will reach 2,244 over the next year, implying 30% upside from its current level of 1,725

    60% confidence
  • S&P 500 will reach 8,338 in the next year

    60% confidence
  • The S&P 500 will reach 8,338 in the next year, implying 28% upside from its current level of 6,506

    60% confidence
  • Consumer discretionary sector will reach 2,244 over the next year, implying 30% upside

    60% confidence
  • Investors are concerned that AI will disrupt the software industry

    60% confidence

Data points we hold from this source

Apple Podcasts · portfolio weight15.8 percent
Apple Podcasts · portfolio weight vgt15.8 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street — Source | Via News | pt.VIA.NEWS